fda green list import alert 66-80 glp-1 apis Issues on GLP-1s Following Launch of “Green List” FDA Green List GLP-1 Alert
Description
At the 2025 American Psychiatric Association meeting, researchers reported that smokers on GLP-1s gained virtually no weight at eight weeks and were 18 percent less likely to relapse than controls in counseling-only programs
Cardiovascular outcome trials for liraglutide, semaglutide, and dulaglutide demonstrated modest blood pressure reductions alongside reduced major adverse cardiovascular events
Real patient stories in reviews show that safe, effective treatment is possible right now
I talked to one person last year who told me that she had had a similar experience throwing up on Wegovy, she said
